SCHEMBL4294396

SCHEMBL4294396

CC(C)(C)C(=O)Nc1ncc(-c2cncc(Br)c2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
LMNA P02545 2/20 0.47
CHEK1 O14757 1/20 0.41
CDK7 P50613 1/20 0.41
KDR P35968 2/20 0.40
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
CCNE1 P24864 2/20 0.39
CDK2 P24941 2/20 0.39
CCNB2 O95067 1/20 0.39
CCNE2 O96020 1/20 0.39
CDK1 P06493 1/20 0.39
CDK4 P11802 1/20 0.39
CCNB1 P14635 1/20 0.39
CCND1 P24385 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4294539 0.82 CHEK1 (0.48) NPC1RAB9ALMNACHEK1CDK7
SCHEMBL3176327 0.79 LIMK1 (0.52) KDRKMT2AKDM4ECCNE1CDK2
SCHEMBL3169992 0.75 PIK3CA (0.46) KDRKMT2ACCNE1CDK2CCNB2
SCHEMBL10079021 0.75 KDR (0.53) NPC1RAB9ALMNAKDRKMT2A
SCHEMBL4292749 0.75 KDR (0.46) CHEK1CDK7KDRKMT2ACCNE1
SCHEMBL9974179 0.74 SMN1; SMN2 (0.55) NPC1RAB9ALMNAMAPTHPGD
SCHEMBL594373 0.72 KDR (0.50) KDRKMT2AMEN1CCNE1CDK2
SCHEMBL25682123 0.72 KDR (0.42) NPC1RAB9ALMNACHEK1CDK7
SCHEMBL25682406 0.72 KDR (0.44) NPC1RAB9ALMNACHEK1CDK7
SCHEMBL31401067 0.71 L3MBTL1 (0.50) NPC1RAB9ALMNAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233896-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
US-20090233896-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
US-20090233896-A1 Inhibitors of checkpoint kinases MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
EP-1893607-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-03-05 EP disclosed
WO-2006135604-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233896-A1 Inhibitors of checkpoint kinases CHEK1, CHEK2, PLK1 NPC1 4591/4885RAB9A 3554/4885LMNA 2223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.